BioPharmaSpec scientists can perform terminal amino acid analysis of your biopharmaceutical, as an indication of the intactness of the molecule. We identify the amino- and carboxy-terminal amino acid sequence(s) of your product and if the molecule exhibits more than one terminal amino acid sequence, the relative amounts of the termini will be determined.
BioPharmaSpec provides gas phase sequencing using Shimadzu instrumentation for automated N-terminal Edman degradation to sequence peptides. This technique is particularly useful in the assignment of the isobaric residues Isoleucine and Leucine during the primary sequence analysis of biopharmaceuticals.
There is no fully reliable method analogous to Edman chemistry for determining the C-terminal amino acid sequence of a biopharmaceutical. For an assessment of the C-termini, BioPharmaSpec scientists will use carboxypeptidase digestion and/or mass-spectrometric mapping strategies. In the latter approach, intactness of a protein C-terminus or the presence of ragged ends can be assessed using data obtained from a peptide map and intact molecular weight analysis of the product, again using a strategy pioneered by our scientists.